Abaloparatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Abaloparatide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
27
Registered trials
22
Result records
9
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Abaloparatide can convert its Synthetic peptide profile and PTH1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Abaloparatide (query alias: abaloparatide) |
|---|---|
| Modality / target | Synthetic peptide; PTH1R; PTH1R agonists |
| Highest global status | Approved |
| Originator | Ipsen SA |
| Active developers | Theramex Ireland Ltd., Radius Health, Inc., Theramex Australia Pty Ltd |
The MCP disease footprint includes Osteoporosis, Osteoporosis, Postmenopausal. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07587775 | Phase 2 | Not yet recruiting | 60 | Improvement in Bone Quality |
| JPRN-jRCT2031250561 | Not Applicable | 募集中 | 4000 | 脳出血、脳梗塞、急性冠症候群を構成要素とした複合心血管系事象 |
| JPRN-jRCTs031250016 | Not Applicable | Recruiting | 200 | Change of bone strength in femoral and vertebra bone at 78 weeks |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: arthralgia = 8.9% ; Adverse Event: arthralgia = 8.9% ; Adverse Event: arthralgia = 8.9%
Effect of PTH Analog on Union Rates of Type II Odontoid Fractures in Older Adults
Phase 2; n=22; evaluation: not stated. Reported fields: Fracture Union(Median) = 0 percentage of total healing (Full Range, 0 - 0); -; -
Bone Turnover Markers Predict Bone Mineral Density Increases with Abaloparatide in Men Similarly to Women: Results From ATOM
Phase 3; n=228; evaluation: Positive. Reported fields: CTx = 0.327 ng/mL
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Abaloparatide addresses Osteoporosis, Osteoporosis, Postmenopausal. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-01-02 | Pharmanovia signs in-licensing deal for novel osteoporosis treatment with Radius Health | Approved | Financial terms not disclosed |
| 2023-03-20 | Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil | Approved | Financial terms not disclosed |
| 2022-07-01 | Pharmbio Korea to market exclusive US osteoporosis treatment | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods for identification and quantitation of abaloparatide and related peptide impurities”. The milestone feed surfaced a patent-application signal described as “Process of making abaloparatide”. The milestone feed surfaced a patent-application signal described as “Animal model having homologous recombination of mouse PTH1 receptor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
